A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
Steven W PipeAli Sadeghi-KhomamiBarbara A KonkleSteve KitchenClaude G NegrierMingjie LiuElena SantagostinoAnnemieke WillemzeLydia Abad-FranchKarin KnobeEkta Seth ChhabraPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2023)
Under- or overestimation occurred with some specific OSAs and most CSAs, which has been previously observed with other modified FVIII replacement products. Efanesoctocog alfa FVIII activity was measured with acceptable accuracy and reliability using several OSA methods and commercial plasma standards.